Alzheimer’s disease: The role for neurosurgery

Julio Leonardo Barbosa Pereira¹, Angela Downes¹, Alessandra Gorgulho¹², Vishal Patel¹, Dennis Malkasian¹, Antonio De Salles¹²

¹Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA, ²HCor Neuroscience, São Paulo, Brazil

E-mail: *Julio Leonardo Barbosa Pereira - julio.pereira@me.com; Angela Downes - angelamd@gmail.com; Alessandra Gorgulho - a_gorgulho@yahoo.com; Vishal Patel - vnpatel@mednet.ucla.edu; Dennis Malkasian - dennis.malkasian@sbcglobal.net; Antonio De Salles - afdesalles@yahoo.com

*Corresponding author

Received: 24 September 13  Accepted: 05 May 14  Published: 05 September 14

This article may be cited as: Pereira JB, Downes A, Gorgulho A, Patel V, Malkasian D, De Salles A. Alzheimer’s disease: The role for neurosurgery. Surg Neurol Int 2014;5:S385-90. Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/9/385/140191

Abstract
Dementia, most commonly caused by Alzheimer’s disease (AD), affects approximately 35 million people worldwide, with the incidence expected to increase as the population ages. After decades of investigation, AD is now understood to be a complex disease that affects behavior and cognition through several mechanisms: Disrupted neuronal communication, abnormal regional tissue metabolism, and impaired cellular repair. Existing therapies have demonstrated limited efficacy, which has spurred the search for specific disease markers and predictors as well as innovative therapeutic options. Deep brain stimulation (DBS) of the memory circuits is one such option, with early studies suggesting that modulation of neural activity in these networks may improve cognitive function. Encapsulated cell biodelivery (ECB) is a device that delivers nerve growth factor to the cholinergic basal forebrain to potentially improve cognitive decline in AD patients. This review discusses the pathogenesis of AD, novel neuroimaging and biochemical markers, and the emerging role for neurosurgical applications such as DBS and ECB.

Key Words: Alzheimer’s disease, deep brain stimulation, dementia, encapsulated cell biodelivery, limbic circuit, neurosurgery, stereotactic surgery

INTRODUCTION

Significant progress has been made in understanding the pathophysiology of Alzheimer’s disease (AD) since Dr. Alois Alzheimer initially identified a patient with progressive loss of short-term memory associated with behavioral disturbances in 1901.¹⁰ AD affects approximately 55 million people worldwide, and was associated with social and healthcare costs exceeding 600 billion USD in 2010. Unfortunately, the incidence of AD is expected to increase over the next decade, posing significant challenges for public health and allocation of health care resources.²⁰,²¹

Today, AD is understood to be a complex disease that affects behavior and cognition through several mechanisms: Disrupted neuronal communication, abnormal regional tissue metabolism, and impaired cellular repair.¹⁰ Anatomically, AD affects many structures of the brain; however, the main focus of damage is in the limbic system [Figures 1 and 2]. Understanding the anatomical nuances of this system opens the possibility for targeting the circuity.¹²,¹³,¹⁸,²²,²³

Extensive cellular and molecular studies in human tissue and animal models have not yet revealed the underlying cause of AD, but much progress has been made in
identifying environmental and genetic risk factors as well as histopathologic markers. The well-known accumulation of β amyloid and aggregation of tau protein are thought to be implicated in the pathogenesis of AD, along with inflammatory microenvironments, impaired response to oxidative stress, and subsequent neuronal degeneration. Genetic loci known to predispose to AD include those on chromosomes 21, 14, 1, and 19, which code for amyloid precursor protein, presenilin 1, presenilin 2, and apolipoprotein E4/E4, respectively. These
Current Food and Drug Administration (FDA)-approved medical therapies directed at improving the function of remaining neurons in the limbic system include cholinesterase inhibitors (ChEIs) which potentiate acetylcholine in the synaptic cleft and N-methyl-d-aspartate (NMDA) receptor antagonists intended to mitigate glutamatergic excitotoxicity. Experimental antiamyloid therapies, attempts to reverse tau deposition, and treatments targeted at minimizing oxidative stresses are also being studied.[3]

Recently, targeting of memory circuits via deep brain stimulation (DBS) has been attempted [Figure 2].[23] DBS has been used with great success in neurodegenerative and neuropsychological applications such as Parkinson’s disease, obsessive compulsive disorder (OCD), and depression. AD as a novel application of this surgical technique has gained the interest of many experts. The result of first phase 1 trial of DBS of the fornix was published in 2010 by Laxton et al. The authors used positron emission tomography (PET) imaging to demonstrate that this therapy was effective in reversing impaired glucose utilization in the temporal and parietal lobes.[19]

Encapsulated cell biodelivery (ECB) is an implanted device that delivers nerve growth factor (NGF) to the cholinergic basal forebrain. Several animal studies have shown that delivery of NGF in basal forebrain could arrest or even reverse the neuronal degeneration process.[11,22,23,36] In 2012, Wahlberg et al. evaluated the safety and clinical efficacy of ECB for use in humans.[16] Currently, a phase II trial is ongoing for evaluating this approach.

Using advances in functional imaging and cognitive neuroscience allows us to investigate the brain and central nervous system (CNS) disorders from an integrated neural network perspective. In this review, we discuss what is known about AD from the fundamental level of genetics and the abnormal biochemical gene products used as biomarkers for AD, as well as the surgical treatments.[11,22] We will then discuss the results of DBS used to treat AD, ECB implant, and the role of functional imaging in fostering the understanding of the disease process, potentially helping identify new and better targets for DBS and other surgical strategies to curb the progress of AD.[23,36]

**IMAGING AND LABORATORY MARKERS IN AD**

It has been suggested that the clinical diagnosis of AD be supplemented by neuroimaging assessments. Magnetic resonance imaging (MRI) and computed tomography (CT) usually demonstrate diffuse cortical atrophy in advanced AD. Newer imaging techniques are being developed to identify the disease at earlier stages.[7,38,39] Initial attempts at this goal focused on standard structural imaging techniques in the hope of identifying imaging markers that could recognize AD in the pre-clinical phase.[24] More recently, several newer imaging and laboratory techniques have been used to identify early AD and are discussed below.[38]

Early identification and classification of abnormal brain changes in patients at risk of AD is important for accurate diagnosis and prognosis, as well as taking therapeutic initiatives. Previously, our knowledge about brain regions affected in various types of dementia was directed by structural imaging modalities such as CT and MRI which offered nonspecific clues. For example, the characteristic atrophy in advanced AD. Newer imaging techniques have been used to identify early AD and are discussed below.[38]

Early identification and classification of abnormal brain changes in patients at risk of AD is important for accurate diagnosis and prognosis, as well as taking therapeutic initiatives. Previously, our knowledge about brain regions affected in various types of dementia was directed by structural imaging modalities such as CT and MRI which offered nonspecific clues. For example, the characteristic atrophy in advanced AD. Newer imaging techniques have been used to identify early AD and are discussed below.[38]

Early identification and classification of abnormal brain changes in patients at risk of AD is important for accurate diagnosis and prognosis, as well as taking therapeutic initiatives. Previously, our knowledge about brain regions affected in various types of dementia was directed by structural imaging modalities such as CT and MRI which offered nonspecific clues. For example, the characteristic atrophy in advanced AD. Newer imaging techniques have been used to identify early AD and are discussed below.[38]

Early identification and classification of abnormal brain changes in patients at risk of AD is important for accurate diagnosis and prognosis, as well as taking therapeutic initiatives. Previously, our knowledge about brain regions affected in various types of dementia was directed by structural imaging modalities such as CT and MRI which offered nonspecific clues. For example, the characteristic atrophy in advanced AD. Newer imaging techniques have been used to identify early AD and are discussed below.[38]
Diffusion tensor imaging (DTI) is a structural neuroimaging modality that tracks the direction of diffusion of water molecules. Based on the degree of diffusivity of water in different tissues, the integrity of white matter tracts can be determined.[26] Hahn et al.[15] combined DTI with fMRI to provide a structural explanation for the functional deterioration as previously described. In their analysis, the authors found significantly decreased white matter connectivity within the posterior DMN, specifically the posterior parietal cortex. Furthermore, this decline in structural and functional connections within the posterior DMN was not explained by atrophy.

In addition to radiolabeled oxygen, another type of PET imaging was developed specifically for use in detecting AD. Pittsburgh compound B (p-PIB) has been used in PET imaging as a marker of amyloid deposition. Unfortunately, amyloid deposition in the initial stage of AD has not been associated with cognitive decline. Besides, reduction in the levels of Aβ (amyloid-beta) through amyloid immunization has not been associated with improved cognition.

Beyond neuroimaging, early AD markers have been sought in the cerebrospinal fluid. Decreased cerebrospinal fluid (CSF) Aβ42 levels and increased tau levels have both been associated with increased brain atrophy in multiple regions. Others have associated such atrophy with CSF apolipoprotein E (ApoE) levels. These CSF markers may thus be of some utility in the early detection of AD.

Several important questions still remain. Among all these candidate markers, is there one, if any, that reliably identifies early stages of AD? Moreover, will the sensitivity and specificity of these markers being evaluated in recent studies reveal important evidence toward more specific criteria to glimpse the disease progress timeline? Combination of several imaging modalities may be advantageous for early detection as well. Overall, however, numerous studies lend support to the consensus that AD is a progressive disease with functional abnormalities preceding structural findings, beginning with the precuneus and posterior parietal lobules.[8,37]

**DBS IN AD**

DBS is a proven therapy utilized for several neurological and psychiatric indications. It was initially found to be beneficial in reducing essential and lately Parkinsonian tremor and other cardinal symptoms of the disease. This result was then extended to treat multiple other conditions, including primary dystonia and OCD, and is in clinical trials for intractable pain, obesity, epilepsy, and restless legs syndrome.[3,8] Based on the effect of DBS on the neural circuitry linking in these systems-level disorders, its potential utility has been translated to AD.

Some investigators have examined the hypothesis that modulation and modification of memory circuits may be possible through implanted electrodes.[2] Rodent studies have examined the role of DBS in improving memory, and found that stimulation of the fornix can induce hippocampal neurogenesis, as detectable on histology using brain-derived neurotrophic factor (BDNF) staining.[2,14] Other animal studies have shown that electrical stimulation of the Papez circuit can reverse memory impairment while also stimulating hippocampal neurogenesis.[2,14]

Based on these promising animal results and improved cognitive scores in one patient undergoing DBS for obesity, Dr. Laxton and colleagues recently conducted an open-label study of DBS for AD.[20] Six patients with early AD were treated with DBS of the fornix bilaterally, over 1 year, monitoring both neuropsychological assessments and FDG-PET scans. Clinical evaluation with the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-COG) and the Mini Mental State Examination (MMSE) suggested a decrease in the rate of cognitive decline. The follow-up PET studies after 1 year demonstrated an increase in cerebral glucose metabolism that was subsequently associated with improved cognitive status. This result is rather encouraging, but it must be interpreted with caution as the study was a small phase I open-label trial conducted without placebo control.[20]

Currently, there are six clinical trials for DBS in AD that are listed by The National Institutes Health of Clinical Trial registry (http://www.clinicaltrials.gov) [Table 1]. Notably, one of these is a double-blind (stimulation on/off)

| Study | Start date | Status   | Responsible party                      |
|-------|------------|----------|----------------------------------------|
| Advance DBS-f in patients with mild probable Alzheimer’s disease | May 2012 | Recruiting | Functional Neuromodulation Ltd |
| Deep brain stimulation of the NBM to treat cognitive deficits in light to moderate Alzheimer’s disease | January 2010 | Unknown | Sturm and Kuhn, University of Cologne |
| Deep brain stimulation for the treatment of Alzheimer’s disease | March 2012 | Recruiting | Rezai, The Ohio State University |
| Deep brain stimulation for Alzheimer’s disease | March 2007 | Unknown | Lozano, University of Toronto |
| Study of the brain stimulation effect on memory impairment in Alzheimer disease | August 2009 | Unknown | Centre Hospitalier Universitaire de Nice |
| Chronic electrical stimulation of hypothalamus/fornix in Alzheimer’s disease | June 2009 | Unknown | Centre Hospitalier Universitaire de Nice |

NBM: Nucleus basalis of Meynert
design, which should prove to be very informative in evaluating the effectiveness of DBS as a therapeutic technique in AD.

**POTENTIAL TARGETS FOR DBS IN AD**

Neuroimaging studies in AD have demonstrated widespread structural and metabolic abnormalities, principally in areas associated with memory functions, as described above. As recent data suggest systems-level defects characterized by alterations in memory circuits, it is reasonable to expect that external stimulation of subareas within the circuitry will ameliorate symptoms. Ultimately, restoration of functional connectivity and induction of hippocampal neurogenesis may be triggered by DBS as well. In this section, we summarize possible DBS targets based upon a review of the literature.

These sites are presented in Figures 1 and 2. The anterior thalamic nucleus (AN) is an important relay in the Papez circuit. Previous studies in rats have shown that AN stimulation at relatively high current disrupted the acquisition of contextual fear conditioning and impaired performance on a spatial alternating task. Stimulation of this area also modulates regional cerebral metabolism as detected by FDG-microPET.

Other investigators argue that DBS of the nucleus basalis of Meynert (NBM) should improve or stabilize memory and cognitive functioning in patients with AD. The hypothesized mechanism involves a facilitation of neural oscillations and the induction of hippocampal neurogenesis. Patients with AD have shown that entorhinal stimulation enhanced the memory of spatial information when applied during learning. These findings suggest that as the major relay of cortical afferent input into the hippocampus, the entorhinal cortex may be the preferable location of DBS electrode placement for memory enhancement.

Medial temporal structures, including the hippocampus and the entorhinal cortex, have long been known to be important in memory formation and recall. Previous studies in refractory epileptic patients have shown that entorhinal stimulation enhanced the memory of spatial information when applied during learning. These findings suggest that as the major relay of cortical afferent input into the hippocampus, the entorhinal cortex may be the preferable location of DBS electrode placement for memory enhancement.

The CA1 region of the hippocampus is another interesting target. An experimental mouse model study showed that application of high-frequency stimulation to isolated hippocampal slices significantly increased synaptic plasticity in the CA1 region and promoted a twofold increase of non-amyloidogenic α-secretase activity, when compared to low-frequency stimulated controls from TgCRND8 mice. In other studies, DBS treatment has been shown to facilitate acquisition of object recognition memory in TgCRND8 mice, relative to their own baseline score before treatment. These results suggest that DBS of the CA1 region may enhance short-term memory in AD, mainly knowing that this region is reachable for implant in humans using advanced imaging and stereotactic techniques.

**NGF IN BASAL FOREBRAIN FOR AD**

NGF is a member of neurotrophin family that plays a role in cholinergic synaptic remodeling in the adult CNS. NGF-producing cells are present in basal forebrain neurons. Neurotrophins influence the survival and death of neuronal and non-neuronal cells. ECB is a combination of gene therapy and device technology that aims the development of a new treatment modality. There is a line of thought supporting the hypothesis that progressive degeneration of forebrain neurons is due to loss of neurotrophic factors available in this region. The exact process leading to neuronal loss is not understood, but deficits in NGF have been proved. Animal studies have shown that NGF has a positive effect in neuronal survival and can even promote cholinergic re-innervation of the frontal cortex. Whether or not NGF injections translate into clinical effects during the course of the disease is yet to be established.

Eriksdotter-Jonhagen et al. used intraventricular infusion of NGF in three patients and observed electroencephalographic (EEG) normalization and glucose metabolism increase in the brain. However, patients developed spinal pain and other side effects, obviating further use of this delivery method of NGF in clinical trials. Wahlberg et al. demonstrated that surgical implantation and removal of EGF-NGF in basal forebrain in AD patients is safe, well tolerated, and feasible. The EGF-NGF may become an important therapeutic option within the neurosurgery arsenal. However, NGFs’ effects on cognitive function improvement and AD progression delay remain to be proven in phase II and III trials.

**NEW TRENDS IN AD**

The treatment options for AD followed until now lead to limited benefits. Research efforts that focused on antiamyloid therapies have been largely unsuccessful, as amyloid deposition appears to be a byproduct of the disease evolution, instead of being a causal factor. Currently, efforts are being directed toward development of new biochemical markers that can be used in neuroimaging, aiming to establish the objective criteria for early, or even preclinical, diagnosis of AD. Early diagnosis becomes important, as the therapies being tried likely could delay the progression of the disease. DBS and ECB implants that deliver NGF represent a novel and attractive strategy for treating this devastating illness and for possibly bringing insights into the pathophysiology of AD.
REFERENCES

1. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry 2002;159:738-45.

2. Arrieta-Cruz I, Pavlides C, Pasinetti GM. Deep brain stimulation in the midline thalamic region facilitates short-term memory in a mouse model of Alzheimer’s disease. Transl Neurosci 2010;1:188-94.

3. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 2011;377:1019-31.

4. Bishop KM, Hofer EK, Mehta A, Ramirez A, Sun LT, Tuszyński M, et al. Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol 2008;215:574-84.

5. Bronstein JM, Taglia M, Alterman RL, Lozano AM, Volkman J, Stefani A, et al. Deep brain stimulation for Parkinson disease: An expert consensus and review of key issues. Arch Neurol 2011;68:165.

6. Brookmeyer R, Evans DA, Hebert L, Lange KM, Heerings SG, Plassman BL, et al. National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimers Dement 2011;7:61-73.

7. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17.

8. Damoiseaux JS, Prator KE, Miller BL, Greicius MD. Functional connectivity networks in Alzheimer’s disease—Revealed by a novel framework to analyze networks. Proc Natl Acad Sci USA 2012;109:3439-44.

9. De Salles AA, Frighetto L, Behnke E, Sinha S, Tseng L, Torres R, et al. Functional Neurosurgery in the MRI Environment. Minim Invasive Neurosurg 2004;47:284-9.

10. Eriksdotter Jönhagen M, Nordberg A, Amberla K, Bäckman L, Ebendal T, et al. Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Göttingen minipig basal forebrain. Mol Ther 2010;18:2164-72.

11. Fjord-Larsen L, Kusk P, Tornøe J, Juliusson B, Torn M, Bjarkam CR, et al. Trophic and enhanced neurogenesis following electrical stimulation of the anterior thalamus in rats treated with corticosterone. Exp Neurol 2011;232:100-4.

12. Gao F, Guo Y, Zhang H, Wang S, Wang J, Wu JM, et al. Anterior thalamic nucleus stimulation modulates regional cerebral metabolism: An FDG-microPET study in rats. Neurobiol Dis 2009;34:477-88.

13. Griere SM, Williams LM, Paul RH, Clark CR, Gordon E. Cognitive aging, and reappraisal. J Alzheimers Dis 2006;9 (3 Suppl):S151-3.

14. Hamani C, Stone SS, Garten A, Lozano AM, Winocur G. Memory rescue and reappraisal. J Alzheimers Dis 2006;9 (3 Suppl):S151-3.

15. Hahn K, Meyerson B, Takahashi T, Miyakawa T, Kurihara T, et al. Functional alterations in memory networks in early Alzheimer’s disease. Brain Res 2009;1265:293-302.

16. Hardy J. Alzheimer’s disease: The amyloid cascade hypothesis: An update and review of key issues. Alzheimers Dis Intell Rev 2005;4:57-67.

17. Hescham S, Lim LW, Jahanshahi A, Steinbusch HW, Prickaerts J, Blokland A, et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol 2009;215:153-9.

18. Hensel E, Howard D, Alsop D, Blacker D, Chisholm G, et al. The relationship between episodic memory and anterior cingulate cortex metabolism in patients with Alzheimer’s disease. J Neuroimaging 2006;16:188-94.

19. Lacan G, De Salles AA, Gorgulho AA, Krali SE, Frighetto L, Behnke EJ, et al. Modulation of food intake following deep brain stimulation of the ventromedial hypothalamus in the vervet monkey. Laboratory investigation. J Neurosurg 2008;108:336-42.

20. Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wenneberg R, Karen R, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol 2010;68:521-34.

21. Lyketsos CG, Targum SD, Pendergrass JC, Lozano AM. Deep brain stimulation: A novel strategy for treating Alzheimer’s Disease. Innov Clin Neurosci 2012;9:10-7.

22. Nagahara AH, Bernot T, Mosenkko R, Brignolo L, Blesch A, Conner JM, et al. Long-term reformation of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol 2009;215:153-9.

23. Niewiadomska G, Mietelska-Porowska A, Mazurkiewicz M. The cholinergic system, nerve growth factor and the cytoskeleton. Behav Brain Res 2011;221:515-26.

24. Petersen RC, Jack CR Jr. Imaging and biomarkers in early Alzheimer’s disease and mild cognitive impairment. Clin Pharmacol Ther 2009;86:438-41.

25. Poulatian N, Zheng Z, Bari AA, Behnke E, Eilias WJ, Desalles AA. Multi-institutional evaluation of deep brain stimulation targeting using probabilistic connectivity-based thalamic segmentation. J Neurosurg 2011;115:995-1004.

26. Rachiele ME, Snyder AZ. A default mode of brain function: A brief history of an evolving idea. Neuroimage 2007;37:1083-90.

27. Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009;6:347-61.

28. Smith GS, De Leon MJ, George AE, Kluger A, Volkow ND, McRae T, et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer’s disease. Pathophysiologic implications. Arch Neurol 1992;49:142-50.

29. Smith GS, Laxton AW, Tang-Wai DF, McAndrews MP, Diaconescu AO, Workman CI, et al. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer Disease. Arch Neurol 2012;69:1141-8.

30. Spelberg RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280-92.

31. Spelberg RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, et al. Functional alterations in memory networks in early Alzheimer’s disease. Neuromolecular Med 2010;12:27-43.

32. Suthana N, Haneef Z, Stern J, Mukamel R, Behnke E, Knowlton B, et al. Memory enhancement and deep-brain stimulation of the entorhinal area. N Engl J Med 2012;366:502-10.

33. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement 2010;6:230-8.

34. Tuszyński MH, Thal L, Pay M, Salmon DP, H E, Baksy R, et al. Phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551-5.

35. Vemuri P, Jones DT, Jack CR Jr. Resting state functional MRI in Alzheimer’s Disease. Alzheimers Res Ther 2012;4:2.

36. Wahlberg LU, Lind G, Almqvist PM, Kusk P, Tornøe J, Juliusson B, et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: A platform technology for restorative neurosurgery. J Neurosurg 2012;117:340-7.

37. Wang J, Xue X, Dai Z, Xia M, Zhao Z, Zhao X, et al. Disrupted functional brain connectivity in individuals at risk for Alzheimer’s disease. Biol Psychiatry 2013;73:472-81.

38. Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer’s disease neuroimaging initiative: Progress report and future plans. Alzheimers Dement 2010;6:202-11.e7.

39. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 2012;8 (1 Suppl):S1-68.